knuts4oe Friday, 05/07/21 10:25:46 AM Re: leifsmith post# 49 Post # of 76 Another quote from the Adam Kaplin article. "One such therapy is MYMD-1, an immunometabolic modulator that is the subject of an upcoming Phase 2 trial to treat immune-mediated depression in COVID-19 patients. The trial is expected to be launched in the last quarter of 2021." Last Fall they told us this trial was due to begin in 2021's 1st quarter, along with the Sarcopenia study. While I fully appreciate Dr. Adam Kaplin laying it all out there in this article, I do not appreciate a 6 month delay in this trial. It indicates that the company is not in control of its own destiny, or they are "operating on a shoestring".